Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from ASKA Pharmaceutical Holdings Co., Ltd. ( (JP:4886) ) is now available.
ASKA Pharmaceutical Holdings Co., Ltd. announced corrections to its financial results for the first quarter of FY2025, specifically regarding the sales transactions of its Vietnamese subsidiary, Hataphar. The company revised its sales recording method to a net basis, impacting net sales and cost of sales by a decrease of 1,680 million yen, without affecting operating or ordinary profits.
The most recent analyst rating on (JP:4886) stock is a Hold with a Yen2305.00 price target. To see the full list of analyst forecasts on ASKA Pharmaceutical Holdings Co., Ltd. stock, see the JP:4886 Stock Forecast page.
More about ASKA Pharmaceutical Holdings Co., Ltd.
ASKA Pharmaceutical Holdings Co., Ltd. operates in the pharmaceutical industry, focusing on the development and sale of pharmaceutical products. The company is based in Tokyo, Japan, and is listed on the Tokyo Stock Exchange under the code 4886.
Average Trading Volume: 75,832
Technical Sentiment Signal: Sell
Current Market Cap: Yen55.73B
See more data about 4886 stock on TipRanks’ Stock Analysis page.